WEX Pharmaceuticals Inc.
TSX : WXI

WEX Pharmaceuticals Inc.

March 27, 2006 13:52 ET

WEX Pharmaceuticals Inc.: Manufacturing Inspection Report

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 27, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that it has received the results of an inspection of its manufacturing plant in China.

This inspection was performed by an independent research organization at the request of our co-development partner, Laboratorios del Dr. Esteve S.A., to ensure that the facilities met GMP (Good Manufacturing Practices) requirements.

The report concluded that Nanning Maple Leaf Pharmaceuticals ("NMLP"), a 97%-owned subsidiary of the Company, is physically and organizationally of a high quality standard and was found to conform to GMP codes. Furthermore, any deficiencies observed at NMLP were determined to be minor and not likely to compromise the purity of the API (Active Pharmaceutical Ingredient) produced, or its safety and efficacy in clinical use.

In anticipation of future late-stage trials and commercialization of the Company's products, the report made several recommendations.

"The report confirmed that NMLP is an acceptable supplier of TTX products for clinical trials up to Phase II. To ensure quality throughout the production chain and strict regulatory compliance, the Company will implement the recommendations of the report in the near future," said Dr. Edge Wang, Chief Executive Officer of the Company.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward-Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.


Contact Information